A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
Clinical trial NCT06365853 · RECRUITING
Trial details
- NCT number
- NCT06365853
- Sponsor
- AbbVie
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-07-29
- Primary completion
- 2026-06-01
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.